重组抗小鼠CD3e单抗(145-2C11) | Syd Labs PA007198.m2a
体内实验级重组抗小鼠CD3e单克隆抗体（克隆号：145-2C11，小鼠IgG2a Kappa，货号：PA007198.m2a）是用哺乳动物细胞生产的重组抗体，纯度>95%，适用于体内和体外研究，比如体内 T 细胞耗竭、体外 T 细胞刺激/激活。Syd Labs PA007198.m2a抗小鼠CD3e抗体不变区为小鼠Mouse IgG2a Kappa (mIgG2a或m2a)，可与重组小鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007198.m2a |
|---|---|
| 产品名称 | 重组抗小鼠CD3e单抗(145-2C11) | Syd Labs PA007198.m2a |
| 英文名 | In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 145-2C11),Mouse IgG2a Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 概述 | Syd Labs提供重组小鼠IgG2a同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | 145-2C11 |
| 同种型 | 小鼠 IgG2a Kappa |
| 免疫源 | 抗小鼠CD3e单抗(克隆号: 145-2C11)是用哺乳动物细胞生产的 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，无稳定剂或防腐剂 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗小鼠CD3e单克隆抗体(克隆号145-2C11)，小鼠IgG2a Kappa用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 1 个月，保存在2 至 8°C。 自收到之日起12个月，保存在-20 至 -70°C。 |
| 注意事项 | PA007198.m2a Syd Labs提供重组小鼠 IgG2a同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA，流式细胞术（FC），中和（neutralization），功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受小鼠CD3e蛋白影响的生物学途径的测定。 |
文献
PA007198.m2a: Syd Labs体内实验级重组抗小鼠CD3e单克隆抗体（克隆号145-2C11，小鼠IgG2a Kappa）（In vivo Grade Recombinant Anti-mouse CD3e Monoclonal Antibody (Clone: 145-2C11), Mouse IgG2a Kappa）
体内实验级重组抗小鼠CD3e单克隆抗体（克隆号145-2C11，小鼠IgG2a Kappa）是针对小鼠T细胞受体（TCR）/CD3复合体中CD3e链（CD3ε）的特异性免疫试剂。CD3e作为T细胞激活和信号转导的核心分子，在细胞免疫应答及T细胞发育中发挥关键作用。145-2C11克隆号抗体不仅广泛应用于流式细胞术（FC）、免疫组化（IHC）和体外T细胞激活，更是体外及体内T细胞清除（Depletion）与免疫调节研究的经典工具。
作为高品质的体内实验级重组抗小鼠CD3e单克隆抗体（克隆号145-2C11），该产品采用重组表达技术和小鼠IgG2a Kappa亚型工程化设计，彻底消除了传统杂交瘤生产中的批次间差异，并具备极高的结合亲和力与特异性。其低内毒素及无叠氮化钠配方可有效避免非特异性细胞毒性，非常适合用于长期动物体内实验（In Vivo）、免疫检查点阻断及肿瘤免疫机制研究，为高质量科研数据提供可靠保障。
抗小鼠CD3e抗体（145-2C11）部分参考文献:
Shihyoung Kim, et al. Toxins (Basel) 2022. PMID: 35740248
“Targeted therapies using anti-CD3 epsilon monoclonal antibodies and immunotoxins represent promising strategies for managing various T-cell-related conditions. However, the use of immunotoxins is frequently associated with vascular leak syndrome, which presents significant clinical safety challenges. This investigation systematically compares the effects of CD3e-conjugated sZAP against the antibody alone, revealing that the sZAP component is primarily responsible for inducing vascular damage.”
Xingjie Ren, et al. Front Immunol 2022. PMID: 36389920
“Depleting T-cells remains a critical method for controlling immune-mediated pathologies, yet achieving selective depletion without destroying regulatory T-cell populations is difficult. This study demonstrates that CD3e-immunotoxins can effectively target high-expressing CD3e T-cells while leaving CD62L low-expressing regulatory T-cells intact. By selectively modulating the T-cell pool, this approach offers a refined method for reshaping organ-specific immune responses.”
3. The establishment and application of CD3E humanized mice in immunotherapy
Ying Wang, et al. Front Immunol 2022. PMID: 36415494
“Humanized mouse models are essential for translating preclinical immunotherapy findings into clinical success. The development of CD3E humanized mice has overcome previous limitations in testing anti-human CD3 therapies within immunocompetent environments. These models provide a robust framework for assessing the efficacy and safety of next-generation T-cell engagers and other CD3-targeting therapeutic agents.”
Maja Buszko, et al. PLoS One 2017. PMID: 28257450
“Anti-thymocyte globulin (ATG) serves as a potent T-cell depleting agent widely used to mitigate rejection in allotransplant settings. Unlike earlier monoclonal anti-CD3 therapies, which caused broad depletion, ATG demonstrates a unique ability to eliminate circulating T-cells while preserving specific regulatory subsets. The use of CD3E humanized mouse models confirms that this differential depletion profile significantly enhances graft survival outcomes.”
5. A humanized CD3ε-knock-in mouse model for pre-clinical testing of anti-human CD3 therapy
Paul S. Moore, et al. PLoS One 2021. PMID: 33596227
“Translational research relies heavily on accurate preclinical models to bridge the gap between initial drug discovery and human clinical trials. This report details the creation of a novel genetic knock-in mouse strain expressing humanized CD3ε, which renders the model susceptible to therapeutic manipulation. Our results validate this humanized platform as a highly effective tool for preclinical assessment of anti-human CD3 antibodies.”